Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

[1]  T. Hour,et al.  CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling , 2019, Cells.

[2]  Conor A. Bradley.  AR-V7 — repress to impress , 2019, Nature Reviews Urology.

[3]  T. Habuchi,et al.  Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High‐Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis , 2019, Clinical genitourinary cancer.

[4]  Paula Esther Moraga-Serrano.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study , 2018 .

[5]  Xiao-li Zhang,et al.  Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer , 2018, Molecular carcinogenesis.

[6]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[7]  Rongsheng Tong,et al.  Multifaceted regulation and functions of YAP/TAZ in tumors , 2018, Oncology reports.

[8]  Christian N. Cunningham,et al.  Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors , 2018, Cancers.

[9]  G. Castoria,et al.  Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications , 2018, Front. Oncol..

[10]  D. Jäger,et al.  Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. , 2017, Urologic oncology.

[11]  C. Collins,et al.  Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy , 2017, Clinical Cancer Research.

[12]  W. Hong,et al.  ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer , 2017, The Journal of Biological Chemistry.

[13]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[14]  Min Hwan Kim,et al.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies , 2016, Cellular and Molecular Life Sciences.

[15]  N. Kyprianou,et al.  Mechanisms of Therapeutic Resistance in Prostate Cancer , 2017, Current Oncology Reports.

[16]  M. Nevalainen,et al.  miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1 , 2016, Molecular Cancer.

[17]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[18]  Jun Yu,et al.  International Journal of Molecular Sciences the Tead Family and Its Oncogenic Role in Promoting Tumorigenesis , 2022 .

[19]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[20]  R. Walther,et al.  Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity , 2015, World Journal of Urology.

[21]  I. Garraway,et al.  YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer , 2015, Nature Communications.

[22]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[23]  C. Evans,et al.  Mechanisms of resistance in castration-resistant prostate cancer (CRPC) , 2015, Translational andrology and urology.

[24]  E. Richardsen,et al.  High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure , 2015, PloS one.

[25]  Nicholas Y. Palermo,et al.  The Hippo Pathway Effector YAP Regulates Motility, Invasion, and Castration-Resistant Growth of Prostate Cancer Cells , 2015, Molecular and Cellular Biology.

[26]  M. Rubin,et al.  ERG induces taxane resistance in castration-resistant prostate cancer , 2014, Nature Communications.

[27]  J. Olsen,et al.  In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth , 2014, Oncogene.

[28]  M. Gleave,et al.  Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility , 2014, PloS one.

[29]  N. Sharifi.  Steroid receptors aplenty in prostate cancer. , 2014, The New England journal of medicine.

[30]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[31]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[32]  B. Mellado,et al.  Nuclear factor‐kappa B and interleukin‐6 related docetaxel resistance in castration‐resistant prostate cancer , 2013, The Prostate.

[33]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[34]  C. Cordon-Cardo,et al.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. , 2012, Cancer cell.

[35]  T. Habuchi,et al.  Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer , 2012, World Journal of Surgical Oncology.

[36]  L. O’Driscoll,et al.  Characterisation and manipulation of docetaxel resistant prostate cancer cell lines , 2011, Molecular Cancer.

[37]  P. Troncoso,et al.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Désarnaud,et al.  Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel , 2011, Cancer biology & therapy.

[39]  R. Eeles,et al.  TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer , 2008, British Journal of Cancer.

[40]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[41]  T. Habuchi,et al.  Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis , 2008, The Prostate.

[42]  E. Sacco,et al.  Long‐term follow‐up of a neoadjuvant chemohormonal taxane‐based phase II trial before radical prostatectomy in patients with non‐metastatic high‐risk prostate cancer , 2007, BJU international.

[43]  Mikhail Teverovskiy,et al.  Improved prediction of prostate cancer recurrence through systems pathology. , 2007, The Journal of clinical investigation.

[44]  Young In Park,et al.  Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[45]  P. Febbo,et al.  Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer , 2005, Clinical Cancer Research.

[46]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[47]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[48]  M. Pfaffl,et al.  Characterisation of gene expression patterns in 22RV1 cells for determination of environmental androgenic/antiandrogenic compounds , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[50]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[51]  W. Ellis,et al.  Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates , 2017, Anti-cancer drugs.

[52]  Desok Kim,et al.  Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. , 2002, The American journal of pathology.